Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary) ; Apremilast
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms POETYK PSO-1
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Jan 2024 Results from NCT04036435, NCT03611751 and NCT03624127, evaluating deucravacitinib safety and efficacy over 2 years in patients, published in the British Journal of Dermatology
    • 20 Dec 2023 Results of secondary analysis evaluating meaningful within-patient score change thresholds for the PSSD using data from this study evaluating the Efficacy and Safety of Deucravacitinib, published in the JAMA Dermatology
    • 18 Dec 2023 Results from POETYK PSO-1 and PSO-2 evaluating the efficacy and safety of deucravacitinib in scalp psoriasis , published in the Journal of the American Academy of Dermatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top